OR WAIT null SECS
© 2024 MJH Life Sciences™ and Pharmaceutical Technology. All rights reserved.
Paper notebooks are the accepted method for recording laboratory data and the ideas generated from that information in the pharmaceutical, biotech, and chemical industries. Nonetheless, the revolution in digital data processing has improved the way data is created, organized, and managed electronically, whether in the form of analytical data, images, documents, or multimedia files. The preservation of such information into a digital form offers the potential for online storage and retrieval, efficient search processes, and worldwide data transmission.
Paper notebooks are the accepted method for recording laboratory data and the ideas generated from that information in the pharmaceutical, biotech, and chemical industries. Nonetheless, the revolution in digital data processing has improved the way data is created, organized, and managed electronically, whether in the form of analytical data, images, documents, or multimedia files. The preservation of such information into a digital form offers the potential for online storage and retrieval, efficient search processes, and worldwide data transmission.
Nonetheless, the benefits of digital data also brings with it a major problem: the ease with which improperly secured information can be copied and manipulated without leaving forensic evidence.
The US Food and Drug Administration believes that the risks of falsification, misinterpretation, and change without leaving evidence are just as great with electronic than with paper records and, therefore, specific controls are required. FDA stated:
"...people determined to falsify records may find a means to do so despite whatever technology or preventive measures are in place. The controls in part 11 are intended to deter such actions, make it difficult to execute falsification by mishap or casual misdeed, and to help detect such alterations when they occur." (1)
Table I: Fraud possibilities on paper-based versus electronic laboratory notebooks.
Therefore, new technologies must safeguard the integrity and authenticity of digital laboratory records, particularly if such records are subject to legal and/or ethical scrutiny. The preservation of digital records integrity is particularly important when they are subject to concerted and possible criminal attack.
FDA's 21 CFR Part 11 regulations outline criteria for the acceptance of electronic records and electronic signatures so that electronic submissions of drug approvals are as genuine and traceable as paper records and handwritten signatures. To be specific, 21 CFR Part 11 applies to:
"...records in electronic form that are created, modified, maintained, archived, retrieved, or transmitted, under any records requirements set forth in agency regulations." (1)
Electronic records guidelines
How can one incorporate this regulation into an electronic solution? First, the system architecture must take into account the managing and controlling of electronic records. To adhere to regulations, electronic records must abide by the following guidelines:
System controls guidelines
Along with electronic records, system controls are needed to verify the data's integrity by assigning the proper privileges and access rights:
Admissibility of electronic records in US court
One of the most important aspects to address when replacing paper-based laboratory notebooks with electronic equivalents is the notebooks' potential use as legal evidence of fraud. Paper notebooks, when backed by clear procedures, are acceptable evidence for laboratory work preferred in the pharmaceutical, biotech, and chemical industries. In practice, the creation and maintenance of electronic laboratory notebooks does not differ from those of paper-based notebooks.
Nevertheless, among certain groups there is still an unfounded fear about whether electronic information can hold up in court under patent or liability laws. Regulatory and governmental organizations such as the European Patent Office, the US Environmental Protection Agency, and FDA have placed electronic records and signatures on equal footing with signed paper documents.
Electronic and paper records are admissible in court under specific rules such as the Business Record Exception (FRE Rule 803[6] Records of Regularly Conducted Activity). Records may be kept in any form, but companies must be able to prove that:
This information can be proven by testimony or written declaration by the custodian or a qualified witness. Records will not be admitted as evidence if they fail to prove these points before a court.
Conclusion
The 21 CFR Part 11 regulation has created a demand for an electronic solution that incorporates standard laboratory notebook practices such as documentation, reviews, version control, signatures, and archiving to meet the needs of laboratories working under any regulatory compliance demands, including good manufacturing, laboratory, and good clinical practices. With the right administration and security tools, user access and records management can be properly monitored and controlled.
It is important to remember that the key to having evidence accepted by a court of law is to prove that the agreed record-keeping procedures were followed and not to focus on the media in which records were stored.
Antony N. Davies is the senior marketing manager at Waters Informatics and Ann McDonough is the corporate communications contact at Waters Corporation, 5 Tech Drive, Milford, MA 01757, tel. 508.482.3729, ann_mcdonough@waters.com
Reference
1. Code of Federal Regulations, Title 21, Food and Drugs, Part 11, "Electronic Records; Electronic Signatures, Final Ruling," Fed. Regist. 62 (54), 13429–13466 (1997), http://www.21cfrpart11.com/files/library/government/21cfrpart11_final_rule.pdf.
*To whom all correspondence should be addressed.